AT treatment also induced Th2 polarization and cytokine secretion and inhibited GVHD development by partially acting through STAT6, a transcription factor essential for Th2 differentiation in response to IL-4 and IL-13 (23, 104, 105). The gene discussed is IL13; the disease is graft versus host disease.